Eltanexor (KPT-8602): Advanced XPO1 Inhibitor for Cancer ...

2026-01-20

Eltanexor (KPT-8602) empowers cancer researchers with a highly potent, second-generation XPO1 inhibitor that demonstrates superior tolerability and efficacy across hematological and solid tumor models. Its unique modulation of the XPO1/CRM1 nuclear export pathway, including Wnt/β-catenin signaling, positions it as a transformative tool for dissecting cancer mechanisms and advancing translational therapeutics.